Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals

monoclonal antibodies represent the fastest growing class of biopharmaceutical products and have a host of applications in medical research, diagnosis, therapy, and basic science. the production of recombinant monoclonal antibodies has revolutionized the generation of immunoglobulins, and their use represents a strategic breakthrough, affecting the global pharmaceutical market for therapeutic proteins. in the present work, a review of scfv, and the number of related patents, has been carried out. the results show that several countries have scfv patents, most notably the united states, china and united kingdom. the target of these scfv antibodies was also assessed and the results demonstrate that most are directed toward cancer therapy.